Pfizer hands Bosulif Phase III to venture-backed drug developer
This article was originally published in Scrip
Pfizer has signed a late-stage clinical development deal with venture-backed drug developer Avillion, to carry out a Phase III trial for cancer drug Bosulif in order to expand the drug's indication to include first-line treatment for chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). While the need to seek the services of a start-up company in developing its drug might be seen as an embarrassment for more pharma companies with more machismo, Pfizer sees the deal as a way of more rapidly exploiting the potential of Bosulif.
You may also be interested in...
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care.